Clinical trials

#Cancer research #Clinical trials #Drug development #Drug discovery #Phase I trial #Phase II trial #Phase III trial

This week in drug discovery (16-20 January)

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not… Read More

#News

Eye
#Clinical trials #Comment #Covid-19 #Eye #Eye health #Ophthalmology

New narrated podcast on ophthalmology

This is the latest episode of the free DDW podcast, “A deep dive into the future of ophthalmology”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Innovation, investment and commitment: Genentech’s approach to the future of ophthalmology” and “… Read More

#News

#Clinical trials #Drug discovery

Exclusive expert insights into clinical trials

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with two experts… Read More

#News

#AbbVie #ABPI #Clinical trials #Eli Lilly #Life sciences #Pharmaceutical industry #Pharmaceuticals #UK #UK government

Pharma firms pull out of UK drug pricing agreement

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going… Read More

#Business & Investment #News #Trending News

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. … Read More

#Business & Investment #Cancer Research #News #Trending News

Non-alcoholic fatty liver disease
#China #Clinical trials #Liver disease #Market reporting #Pharmaceuticals

China’s clinical trial activity in NAFLD increasing

China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM).   As a result, the number of clinical trials conducted in the country for this indication is gradually increasing, driven… Read More

#Business & Investment #News

Acute myeloid leukaemia
#Acute Myeloid Leukaemia #Biopharmaceuticals #Clinical trials #Drug development

Initially positive findings from AML treatment study 

A study by Ellipses Pharma, a global drug development company focused on accelerating the development of new oncology treatments, has presented preliminary data from the first in human Phase I/II trial of EP0042, a dual FLT-3 an Aurora kinase inhibitor, in patients with acute myeloid leukaemia (AML). … Read More

#News

#Clinical trials #Covid-19 #Data #Disease surveillance #Global.health #Immunology / Virology & Vaccines

Fortifying vaccines through disease surveillance and data reporting  

Shelley McLendon, SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. There, McLendon spoke on the topic of fortifying vaccines against future pandemics, specifically discussing: The importance of disease surveillance and reporting with regard to emerging… Read More

#Exclusive Content

Scientist in laboratory
#Antibodies #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Janssen #Leukaemia #Myeloma #Oncology

New trial data revealed in potential myeloma and leukaemia treatments

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase… Read More

#Cancer Research #News

Cancer cells
#Acute Myeloid Leukaemia #Cancer research #Cell and gene therapy #Clinical trials #Gene editing

First AML patient successfully transplanted with investigational drug 

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukaemia (AML).   The data observed from the first treated patient support the… Read More

#Cancer Research #News

Myeloma
#Cancer research #Clinical trials #Diagnostics #Market reporting #Report

Report: inequalities in access to myeloma clinical trials in Europe 

Myeloma Patients Europe (MPE) has launched an advocacy report on addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE).   The report, led by the MPE CEE Workgroup on Access, found huge inequalities for patients, confirming reports from MPE CEE members about a lack… Read More

#Cancer Research #Market Reports #News

#AI / data analytics / healthtech / informatics #Clinical trials #Covid-19 #Drug development #Healthcare #Public health #Regulatory

Drug development practices to improve public health policy 

Dr Andrew Garrett, Executive Vice President of Scientific Operations at ICON, explores the benefits of integrating some of the validation and standardisation practices already developed for PIs into the practices around NPIs and public health data; outlines some of the practices that can be implemented in order to do this;… Read More

#Exclusive Content #Opinion #Regulatory

#Clinical trials #Rare disease

Positive Phase I results for rare disease inhibitor 

Affibody’s licensee Rallybio Corporation has announced positive topline results from a Phase I single ascending dose study in healthy participants of RLYB116, a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalised… Read More

#News

Climate change
#Clinical trials #COP27 #Supply chain #Sustainability

Pharma companies team-up to reduce emissions  

Seven pharmaceutical companies have announced a joint initiative to reduce near-term emissions and help develop net zero health systems.   CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced commitments to tackle climate change through the Sustainable Markets Initiative (SMI) Health… Read More

#News

AI brain
#AI / data analytics / healthtech / informatics #ALS #Biotechnology #Clinical trials #Drug discovery #Genomics

AI-driven biotech initiates Phase I trial for ALS drug 

Verge Genomics, a clinical-stage, tech-enabled biotechnology company using artificial intelligence (AI) and human data to transform drug discovery, has announced today that the first subject has been dosed in a Phase I clinical trial of VRG50635 for amyotrophic lateral sclerosis (ALS).  VRG50635 is a small molecule inhibitor… Read More

#News

#Citeline #Clinical trials #Mergers and acquisitions #Norstella #Pharma intelligence

Merger creates $5 billion pharma technology company 

Norstella and Citeline (formerly Pharma Intelligence) have merged to form a $5 billion global company, one of the largest pharma intelligence solutions providers on the market.  Norstella now has more than 1,500 employees across its five brands: Evaluate, MMIT, Panalgo… Read More

#Business & Investment #News